What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Chemotherapy
Beow Y. Yeap mainly focuses on Lung cancer, Surgery, Internal medicine, Cancer research and Gefitinib.
His Lung cancer study incorporates themes from Cancer, Gene rearrangement and Carcinoma.
His Internal medicine research incorporates elements of Gastroenterology and Oncology.
The study incorporates disciplines such as Mutation, KRAS, EGFR inhibitors and Protein kinase B in addition to Cancer research.
His Gefitinib study combines topics from a wide range of disciplines, such as T790M, Tyrosine kinase and Erlotinib.
The concepts of his Anaplastic lymphoma kinase study are interwoven with issues in Immunohistochemistry and Crizotinib.
His most cited work include:
- Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK (1441 citations)
- Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC (789 citations)
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. (731 citations)
What are the main themes of his work throughout his whole career to date?
His primary scientific interests are in Internal medicine, Oncology, Surgery, Lung cancer and Radiation therapy.
His Internal medicine study frequently intersects with other fields, such as Gastroenterology.
His studies deal with areas such as Lung, Retrospective cohort study, Phases of clinical research and Olaparib as well as Oncology.
His research on Surgery often connects related topics like Lymphoma.
As a part of the same scientific study, he usually deals with the Lung cancer, concentrating on Cancer research and frequently concerns with Tyrosine kinase.
In his work, Quality of life is strongly intertwined with Prospective cohort study, which is a subfield of Radiation therapy.
He most often published in these fields:
- Internal medicine (44.37%)
- Oncology (32.15%)
- Surgery (23.15%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (44.37%)
- Oncology (32.15%)
- Radiation therapy (19.61%)
In recent papers he was focusing on the following fields of study:
Beow Y. Yeap mostly deals with Internal medicine, Oncology, Radiation therapy, Lung cancer and Cancer research.
The Oncology study combines topics in areas such as Clinical trial, Olaparib and Chemotherapy, Temozolomide.
His Radiation therapy research is multidisciplinary, relying on both Medulloblastoma, Proportional hazards model, Cohort and Hepatocellular carcinoma.
His work focuses on many connections between Hepatocellular carcinoma and other disciplines, such as Gastroenterology, that overlap with his field of interest in Hazard ratio.
His Lung cancer study frequently links to related topics such as Tyrosine kinase.
His Cancer research research is multidisciplinary, incorporating elements of Cancer cell, Refractory and Immunotherapy.
Between 2018 and 2021, his most popular works were:
- Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. (116 citations)
- Combination Olaparib and Temozolomide in Relapsed Small Cell Lung Cancer (40 citations)
- Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity. (38 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Chemotherapy
His scientific interests lie mostly in Internal medicine, Lung cancer, Oncology, Cancer research and Lorlatinib.
His study on Retrospective cohort study, Hazard ratio, Radiation therapy and Propensity score matching is often connected to MEDLINE as part of broader study in Internal medicine.
His Radiation therapy research includes elements of Adverse effect and Survival analysis.
His Lung cancer research integrates issues from Mutation and Tyrosine kinase.
Beow Y. Yeap interconnects Clinical trial, Disease and Chemotherapy in the investigation of issues within Oncology.
Beow Y. Yeap combines subjects such as Cancer, Nivolumab, Ipilimumab and Immunotherapy with his study of Cancer research.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
